Dynavax Completes Merger and Prepares Nasdaq Delisting

Dynavax ( (DVAX) ) has issued an announcement.

Dynavax is a biopharmaceutical company focused on developing and commercializing vaccines and immunology-based treatments, with a particular emphasis on leveraging its proprietary technologies in infectious disease prevention. The company operates in a competitive life sciences market and had been publicly listed on the Nasdaq Global Select Market prior to its acquisition and subsequent delisting following the merger completed on February 10, 2026.

On February 10, 2026, Dynavax completed a merger following a tender offer in which approximately 73.92% of its outstanding shares were validly tendered, resulting in the company becoming an indirect wholly owned subsidiary of a parent entity and triggering cash-based conversion terms for its 2026 and 2030 convertible senior notes at an offer price of $15.50 per share equivalent. The transaction terminated Dynavax’s equity incentive and stock purchase plans, cashed out or converted options and restricted share units into cash-based awards with modified vesting, reshaped the board and management lineup, and set in motion the delisting of its shares from Nasdaq and the deregistration of its securities, materially altering the capital structure and governance framework for existing stakeholders.

The most recent analyst rating on (DVAX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Dynavax stock, see the DVAX Stock Forecast page.

Spark’s Take on DVAX Stock

According to Spark, TipRanks’ AI Analyst, DVAX is a Outperform.

The score is driven primarily by improving fundamentals (revenue and free cash flow growth with manageable leverage) and strong, positive strategic execution from the latest earnings call, further reinforced by the announced Sanofi cash acquisition at a premium. Offsetting factors include ongoing profitability/ROE weakness, overbought technical conditions, and limited valuation support due to a negative P/E.

To see Spark’s full report on DVAX stock, click here.

More about Dynavax

Dynavax is a biopharmaceutical company focused on developing and commercializing vaccines and immunology-based treatments, with a particular emphasis on leveraging its proprietary technologies in infectious disease prevention. The company operates in a competitive life sciences market and had been publicly listed on the Nasdaq Global Select Market prior to its acquisition and subsequent delisting following the merger completed on February 10, 2026.

Dynavax’s acquisition closed on February 10, 2026, when a tender offer and subsequent short-form merger made the company an indirect wholly owned subsidiary of a parent entity, triggering changes to its convertible notes, equity plans, and corporate governance. The merger redefined conversion terms for its 2026 and 2030 convertible senior notes into fixed cash-based consideration, terminated multiple equity incentive plans, cashed out or converted equity awards into deferred cash awards, led to board and officer reconstitution, and culminated in the delisting of Dynavax shares from Nasdaq and the planned deregistration of its stock.

Average Trading Volume: 3,159,492

Technical Sentiment Signal: Buy

Current Market Cap: $1.82B

Learn more about DVAX stock on TipRanks’ Stock Analysis page.